Beijing New drug industry 118 million Hangzhou real estate purchase

Beijing New Drug industry (002020) announcement, the company signed a subscription book on May 4, to buy Hangzhou UDC Times Building Business Office 24th, 25-storey property.　　The transaction of the total room for RMB 118 million yuan, is expected to affect the company's profit of about 9.7 million yuan each year. The bulletin shows that the UDC Times Mansion is located in the central business district of Qianjiang New Town, Hangzhou, the core area, the road intersection with the river. The building is expected to be delivered by August 2011.　　The total area of property to be purchased by the company is 3025.52 square meters. May 4, the company and Hangzhou Hualian Real Estate Co., Ltd. signed a subscription book, and paid a deposit of 10 million yuan, has not signed a formal sale and purchase contract. The 24th floor unit Price is 38220 yuan/square meters, the 25th floor unit Price is 38510 yuan/square meters, each parking space price is 250,000 yuan.　　Payment will be by Bank mortgage payment, down payment 50%, 5-year mortgage, the first payment of 59.037 million yuan is expected to be paid in June this year, mortgage payments are expected to start in August, the monthly payment of about 1.2 million yuan. The announcement said that the company's account has its own capital of more than 60 million yuan, the transaction of the first payment of 60 million yuan, of which 30 million of its own funds to pay, another 30 million yuan to be resolved through bank loans (to the company's real estate and land for mortgage loans). The mortgage payment will be settled by the company's sales.　　At the same time, in order to reduce payment pressure, the company plans to sell located in Hangzhou, No. 203 Chao Hui Road, Hangzhou Blue Square, the 15th floor office. The first floor of the property purchased as the company's future headquarters office use, a layer as an investment property. Beijing New drug industry headquarters in Zhejiang Province Xinchang County, production base in Zhejiang Xinchang, Zhejiang Shangyu, Jiangxi Guangfeng, Inner Mongolia Four, research and development base in Shanghai Zhangjiang, sales headquarters in Hangzhou, Zhejiang, headquarters management has not been adapted to the current management pattern.　　The company plans to unify the management headquarters and sales headquarters in Hangzhou office. However, the new drug industry said that the transaction short-term to the company constitutes a certain financial pressure, the company is expected to increase the annual financial costs of about 6.3 million yuan, increase depreciation of about 3.4 million yuan, the total impact of profit of about 9.7 million yuan.